Volume 130, Issue 9

Cover Figure: Correcting selinexor-induced thrombocytopenia. See the article by Machlus et al.

WASHINGTON, August 31, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy
This manuscript breaks new ground and reports the ability to use thrombopoietin in women with immune thrombocytopenia during pregnancy.

Targeting BCL-2 in B-cell lymphomas
In a comprehensive Perspective, the authors describe the utility of BCL-2 antagonists in the treatment of B-cell malignancies.

HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities
In this Blood Spotlight, the authors explore basic and clinical aspects of HLA-DP locus mismatching in unrelated hematopoietic cell transplantation.

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
The authors describe the clinical course of a series of patients with myelofibrosis treated with ruxolitinib with a focus on the significant prognostic impact of newly emerging gene mutations and the fate of patients after discontinuation of ruxolitinib.

Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review
Can oral anticoagulants be used to treat heparin-induced thrombocytopenia (HIT)? Warkentin and coworkers report their recent experience and present the largest available evidence for the efficacy of oral anticoagulants in patients with acute or subacute HIT.

Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma
This study on adult T-cell leukemia/lymphoma, an aggressive malignancy of activated T-cells, brings convincing in vivo evidence that highly specific cyclin-dependent kinase 9 inhibition could be therapeutically effective.

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis
These studies provide significant new insights into the mechanisms by which selinexor, a member of the growing family of selective inhibitors of nuclear export anticancer drugs, causes thrombocytopenia and how to correct the thrombocytopenia.


This week's complete table of contents

Why Submit to Blood?



Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.